Trastuzumab Emtansine（T-DM1）

製品コードD4003 別名: Ado-Trastuzumab emtansine 純度：99.59%

Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.This product is supplied as 10mg/ml PBS solution.

CAS No. 1018448-65-1

サイズ	価格(税別)	在庫状況
1mg	JPY 145500	国内在庫あり
1mg*5	JPY 445500	お問い合わせ

代表番号: 045-509-1970\|電子メール：sales@selleck.co.jp よく尋ねられる質問

質量管理及び製品安全説明書

現在のバッチを見る： D400301 純度： 99.59% タンパク質濃度： 10.8mg/ml 内毒素：＜1EU/mg

99.59

HER2阻害剤の選択性比較

生物活性

製品説明	Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.This product is supplied as 10mg/ml PBS solution.

製品説明

CAS No.	1018448-65-1
Molecular Weight	145000
DAR	3.6
ADC antiody	Trastuzumab
ADC cytotoxin	DM1
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Shipping	Shipped under low temperature conditions

各種クローンの論文数比較

^*Selleckは、市場の主要なクローンを収集し、2024年9月までの文献での使用状況を調査しました。その結果、Selleckの選定クローンが最も広く使用されていることが示されました。

臨床試験

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06348134	RECRUITING	Drug: Trastuzumab emtansine\|Drug: Pertuzumab Injection\|Drug:	Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2-positive Breast Cancer; Breast Cancer	University of Chicago	2025-03-18	PHASE2
NCT04589845	ACTIVE_NOT_RECRUITING	Drug: Entrectinib\|Drug: Entrectinib\|Drug: Alectinib\|Drug: At	Solid Tumors	Hoffmann-La Roche	2021-01-18	PHASE2
NCT07578116	NOT_YET_RECRUITING	Drug: Cyclin-Dependent Kinase 4 Inhibitor\|Drug: Cyclin-Depen	Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma; Oligometastatic Breast Carcinoma	SWOG Cancer Research Network	2027-03-09	PHASE3
NCT06830889	RECRUITING	Drug: BL-M07D1\|Drug: T-DM1	HER2-positive Breast Cancer	Sichuan Baili Pharmaceutical Co., Ltd.	2025-06-03	PHASE3
NCT01042379	RECRUITING	Drug: Standard Therapy\|Drug: AMG 386 with or without Trastuz	Breast Neoplasms; Breast Cancer; Breast Tumors; Angiosarcoma; TNBC - Triple-Negative Breast Cancer; HER2-positive Breast Cancer; HER2-negative Breast Cancer; Hormone Receptor Positive Tumor; Hormone Receptor Negative Tumor; Early-stage Breast Cancer; Locally Advanced Breast Cancer	QuantumLeap Healthcare Collaborative	2010-03-01	PHASE2
NCT06126640	ACTIVE_NOT_RECRUITING	Drug: SHR-A1811\|Drug: Trastuzumab Emtansine	HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy	Jiangsu HengRui Medicine Co., Ltd.	2023-11-20	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-02-17)

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須